Funding Received
$14 Million in 1 Round from 1 Investor
Most Recent Funding
$14 Million Series A on April 24, 2012
Description:
Telsar Pharma develops Astellas drugs for common inflammatory bowel diseases.
Categories:
Biotechnology

Detailed Description

Update

Telsar Pharma Inc., a new company that will develop an Astellas drug for a common inflammatory bowel disease.

Funding Rounds (1) - $14M

Update

Investors (1)

Update